NEW YORK, April 29, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Pentair plc. (NYSE: PNR), Spectranetics Corporation (NASDAQ: SPNC), Biogen Inc. (NASDAQ: BIIB), Agenus Inc. (NASDAQ: AGEN), and Natural Resource Partners LP (NYSE: NRP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
PNR Research Report: ( http://get.analystsreview.com/pdf/?c=Pentair%20plc.&d=29-Apr-2015&s=PNR ),
SPNC Research Report: ( http://get.analystsreview.com/pdf/?c=Spectranetics%20Corporation&d=29-Apr-2015&s=SPNC ),
BIIB Research Report: ( http://get.analystsreview.com/pdf/?c=Biogen%20Inc.&d=29-Apr-2015&s=BIIB ),
AGEN Research Report: ( http://get.analystsreview.com/pdf/?c=Agenus%20Inc.&d=29-Apr-2015&s=AGEN ),
NRP Research Report: ( http://get.analystsreview.com/pdf/?c=Natural%20Resource%20Partners&d=29-Apr-2015&s=NRP ).
Analyst Update: Results Update, Clinical Trials Results, Financial Strategy Announcement
Reviewed by: Rohit Tuli, CFA®
U.S. stocks closed mixed on Tuesday as investors remained vigil over tech earnings and the Federal Reserve's concluding statement on Wednesday. The Dow Jones Industrial Average advanced 0.40%, to close the day at 18,110.14, and the S&P 500 gained 0.28%, to 2,114.76. However, the NASDAQ Composite was down 0.10%, to finish the session at 5,055.42. European stocks tumbled on Tuesday amid concerns over Federal Reserve's meeting outcome. Germany's DAX 30 fell 1.89%, France's CAC 40 lost 1.81%, and London's FTSE 100 ended 1.03% lower on Tuesday. Meanwhile, Asian stock markets mostly closed lower on Tuesday. The Shanghai Composite Index and Australia's S&P ASX both fell on Tuesday, while Hong Kong's Hang Seng index was flat.
On April 21, 2015, Pentair plc announced that its Q1 FY15 sales of $1.5 billion were down 10% on year-over-year basis. First quarter 2015, earnings per diluted share from continuing operations were $0.65, down 8% from adjusted EPS of $0.71 in the first quarter of last year.
Spectranetics Corporation stock fell 23.57% on Friday, April 24, 2015 to close at $26.52. This followed the Company's announcement of its Q1 FY15 results a day earlier. The Company reported a Q1 FY15 net loss of $27.3 million, or $0.65 per share, compared with net loss of $5.7 million, or $0.14 per share, for Q1 FY14.
Shares of Biogen fell by over 6.6% to close at $401.71 on April 24, 2015. On the same day, Biogen announced first quarter 2015 results that missed on earnings and revenues estimates. Net income attributable to Biogen rose to $822.5 million, or $3.49 per diluted share during the quarter, from $480 million, or $2.02 per diluted share, same period a year earlier.
On April 24, 2015, Agenus announced final results from a large-scale Phase 3 study of GlaxoSmithKline's malaria vaccine candidate, RTS,S. The study demonstrated a statistically significant reduction against malaria in children who received RTS,S followed by a booster shot of the vaccine at 18 months.
On 22 April, Natural Resource Partners announced a long-term plan to strengthen its balance sheet, reduce debt and enhance liquidity.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review